Abstract: 【Abstract】 Objective To detect the expression of HBx in HCC and analyze its relationship with disease-free survival (DFS) in HBV-related HCC. To evaluate the detection performance of HBx antigen in human serum. Methods Immunohistochemical staining was utilized to detect the expression of HBx in 35 HBV-related HCC tissues, and results were analyzed with clinical data. Enzyme-linked immunosorbent assay (ELISA) was applied to detect the HBx antigen in human serum. Results HBx positive ratios were 20/35 (57.14%) in HCCs, with 15/24 (62.50%) of HBsAg positive and 5/11 (45.45%) of HBsAg negative cases respectively. The poorly differentiated ratio of HBx positive (9/20, 45.00%) was significantly higher than that of HBx negative (2/15, 13.33%) cases (P<0.01). Disease free survival (DFS) of HBx positive and negative group was estimated by Kaplan-Meier method and compared by log-rank test. The results showed poor DFS in HBx positive group (P=0.03). ELISA could efficiently detect HBx antigen in human serum with 48/77(62.34%) positive. Conclusions The expression of HBx is correlated with tumor pathological grading and poor DFS of HCC patients. ELISA can efficiently detect HBx antigen in human serum.

Key words: Hepatocellular Carcinoma, Hepatitis B Virus, Hepatitis B Virus X Protein, Tumor Pathological Grading, Disease-Free Survival　

摘要： 【摘要】 目的 检测乙型肝炎病毒x蛋白(HBx)在肝细胞癌中的表达及其与患者预后的关系,并探讨人血清HBx抗原的检测。方法 用免疫组化法检测35例肝癌患者肿瘤组织中HBx蛋白的表达,与临床资料进行相关分析;应用酶联免疫吸附法(ELISA)检测77例人血清中HBx抗原的表达情况。结果 肝癌组织中HBx的总体阳性检出率为20/35(57.14%),其中乙型肝炎病毒表面抗原(HBsAg)阳性者HBx的阳性率为15/24(62.50%),而HBsAg阴性者HBx的阳性率为5/11(45.45%);HBx阳性与HBx阴性的肿瘤组织低分化比率分别为9/20(45.00%)及2/15(13.33%),差异有统计学意义(P<0.01);HBx阳性肝癌患者的无病生存期(DFS)明显短于HBx阴性患者(Kaplan-Meier法及log-rank检验,P=0.03)。ELISA检测人血清中HBx抗原的总阳性率为48/77(62.34%)。 结论 肝癌肿瘤组织中HBx的表达与患者无病生存期呈负相关,ELISA法能有效检测人血清中HBx抗原的表达。

关键词: 肝细胞癌, 乙型肝炎病毒, 乙型肝炎病毒X蛋白, 肿瘤病理分级, 无病生存期